FDA granted approval and accepted sNDA for Bristol-Myers Squibb drugs, alongside EMA validation and a collaboration agreement with Merck.
2 reports, 2 independent
Updated Jul 24
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted approval and accepted sNDA for Bristol-Myers Squibb drugs, alongside EMA validation and a collaboration agreement with Merck.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
- FDA
-
MRK
Visual artist and director.
Nothing else this week.
Related events
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- Generic medicine services are seeking approval for launch from the FDA.
- BMD is listed on Nasdaq and received positive feedback from the FDA regarding its Phase 3 drug protocol.
Coverage
Newest first; wire copies grouped- ZacksBristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock? Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The stock r
- Business WireBristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Global